Approximately 60% of AML cases reportedly harbored mutations in FLT3, N-RAS, p53 or cKIT gene, while it remains unclear which kind of genetic events are involved in the disease progression in the remaining cases. In addition, it remains unclear why GATA1 mutations uniquely occur in DS children. Further studies are required to elucidate this issue, although the same etiology might be involved in the acquisition of GATA1 mutations and the evolution of AMkL from TMD.
T-cell signaling and costimulatory molecules in B-chronic lymphocytic leukemia (B-CLL): an increased abnormal expression by advancing stage
TO THE EDITOR B-cell chronic lymphocytic leukemia (B-CLL) is a clonal lymphoproliferative disorder with a highly variable clinical course and prognosis, which is associated with immune dysregulation, especially in the progressive phase. The leukemic clone may be regulated by inhibitory or growth-promoting signals by autologous T cells. These cells have been shown to exhibit functional abnormalities related to disease activity. 1, 2 The adhesion molecule CD54 is constitutively expressed on T cells and upregulated during immune activation. The CD3z chain connects the T-cell receptor (TCR) to the intracellular signaling machinery leading to T-cell activation. 3 For an efficient T-cell activation engagement of costimulatory receptors is required as well. A balance between the CD28-and CTLA-4-mediated regulatory signals seems to be indispensable. Upon TCR stimulation accompanied by CD28/B7 interaction, cytokine production and upregulation of cell surface molecules leading to T-cell activation and proliferation occur. Lack of CD28 costimulation induces either T-cell apoptosis or anergy. 3 Reduced IL-2 production by T cells, IL-2 receptor downregulation and G1-phase arrest is induced when CTLA-4 binds to the B7 family receptors. CTLA-4-deficient mice died from a lymphoproliferative disease, characterized by multiple organ infiltration and T-cell activation. 4 Blocking of the CTLA-4/B7 interaction induced tumor rejection and immunity to tumor rechallenge in a T-cell-dependent manner. The CD28 molecule is constitutively expressed on T cells, while CTLA-4 is primarily localized intracellular and only transiently is expressed on the surface upon activation. The aim of the present study was to analyze the expression of CD54, CD28 and CTLA-4 molecules, as well as the CD3z chain in T cells of B-CLL patients and relate to the stage of the disease. B-CLL patients with progressive (n ¼ 7) and nonprogressive (n ¼ 11) disease entered the study. The criteria for diagnosis and disease progression have been described elsewhere. 5 Agematched healthy donors (n ¼ 11) were used as controls. T cells were enriched from peripheral blood mononuclear cells by nylon wool separation. Direct and indirect surface and intracellular immunofluorescence staining were performed. Cells were analyzed by flow cytometry using a FACScan and data were processed by the CellQuest software. For comparison of independent variables, the Kruskal-Wallis and Mann-Whitney U-test were applied. The Wilcoxon signed-rank test was used for pairwise variables. Spearman's rank correlation measured the correlation between marker expression and disease stage. All statistics were performed using the Stat View software.
A higher frequency of CD4 þ /CD54 þ T cells was found in patients with progressive disease compared to controls (Po0.01) ( Figure 1 ). In the CD8 subset, the frequency of CD54 þ cells was higher than within the CD4 subset in patients with nonprogressive disease and in controls (Po0.05 and 0.01) ( Table 1) . Moreover an increased frequency of CD4 þ /CD54 þ T cells was 5 These authors equally contributed to this work Correspondence noted by advancing stage (Po0.01). The proportion of CD4 þ /z chain þ cells were decreased both in patients with nonprogressive and progressive disease as compared to controls (Po0.01 and 0.001) (data not shown). In patients with progressive disease, the frequency of CD8 þ /z chain þ cells was lower than in controls (Po0.01). Furthermore, a lower proportion of CD8 þ /z chain þ cells as compared to CD4 þ /z chain þ cells was found in patients with progressive disease (Po0.05) ( Table 1) . A gradual decrease in the frequency of CD8 þ /z chain þ T cells was noted by advancing disease (Po0.05). A lower frequency of the CD8 þ / CD28 þ cells as compared to the CD4 counterpart was observed in controls (Po0.001) as well as patients with nonprogressive (Po0.01) and progressive (Po0.05) disease (Table 1 ). The frequency of CD4 þ /CD28 þ cells was lower in patients with nonprogressive and progressive disease as compared to controls (Po0.05 and o0.001, respectively) and a gradual decrease by advancing stage was noted (Po0.01). In patients with progressive disease the frequency of CD4 þ /surface(s)CTLA-4 þ T cells and CD8
þ /sCTLA-4 þ cells was higher than in nonprogressive disease (Po0.01 and 0.01) and controls (Po0.01 and 0.01) (Figure 2 ). Moreover, in nonprogressive patients, the proportion of CD4 þ /sCTLA-4 þ cells was higher than that of CD8 þ /sCTLA-4 þ (Po0.05). A gradual increase of sCTLA-4 þ T cells by advancing stage was found, both for the CD4 and CD8 T cell subsets (Po0.0001 and 0.001). The cytoplasmic(c) expression pattern was similar to that on the surface. Overall, the proportion of CD4 þ /cCTLA-4 þ cells was higher than that of CD8 þ /cCTLA-4 þ (Po0.05) in all groups (Table 1) . In progressive disease, a higher frequency of cCTLA-4 þ T cells was found both in the CD4 and CD8 subsets in comparison to controls (Po0.01 and 0.05). Increased frequencies of cCTLA-4 þ cells in CD4 and CD8 subsets were noted by advancing disease (Po0.001 and 0.01).
The mechanisms of the T-cell dysfunction in B-CLL are not yet fully understood. Initiation of a T-cell response requires priming by antigen-presenting cells in the presence of B7 costimulation. As T cells become activated by TCR signaling and CD28 costimulation, the role of CTLA-4 in regulating an ongoing response becomes critical. The present results and those reported earlier suggest a profound T-cell dysregulation in B-CLL. A reduced expression of CD3z chain and CD28 in a stagedependent manner has been reported earlier.
1,2 Our results confirm these data and in addition demonstrate a predominant z chain downregulation in the CD8 subset in patients with progressive disease. A simultaneous downregulated z chains and CD28 receptors might be due to a chronic antigenic stimulation. 6 Our results support previous suggestion of an ongoing in vivo activation of T cells in B-CLL. The reduced CD28 expression may cause an impaired ability of T cells to interact with dendritic cells as well with the leukemic cells, which express low levels of CD80/CD86 leading to impaired interaction with immune cells.
To our best knowledge, this is the first report on an increased surface and intracellular expression of CTLA-4 on T cells in patients with progressive B-CLL. Previously, a high intracellular CTLA-4 expression was demonstrated in CD2 þ cells in B-CLL. 1 CTLA-4 mediates inhibitory functions, impeding T-cell activation during an antitumor response. 4 In mice and humans, blocking of the CTLA-4/B7 interaction enhanced a T-cell response. High expression of CTLA-4 have been reported in tumor areas where T-cell functions were inhibited. 7 The high frequency of CTLA-4-expressing T cells in patients with progressive disease might contribute to a T-cell-mediated inhibition of cellular immune functions. Upregulation might be due to an ongoing activation or an intrinsic property of T cells associated with the disease.
The increased CD54 expression on T cells in progressive disease stage is also a novel finding. Apart from adhesion function, this receptor is involved in signal transduction. þ subsets. For symbols see Figure 1 .
nn Indicate a statistically significant difference (Po0.01) comparing patients with nonprogressive and progressive disease.
y and yy Indicate a statistically significant difference (Po0.05 and o0.01, respectively) comparing control donors and patients with progressive disease.
patients. 5 T cells with an enhanced expression of CD54 and a high IL-4 content were found in patients with asthma. 8 The biological significance and mechanism of upregulation of CD54 on T cells in B-CLL need, however, further clarification.
This study showed that several critical activation/interaction molecules on T cells in B-CLL are abnormally expressed, and more pronounced by advanced stage. These defects may contribute to immune dysfunction responsible for immunological abnormalities and an impaired regulation of the leukemic clone. Therapeutic attempts might be instituted to restore T-cell functions, those interventions may be crucial when developing immunotherapeutic concepts, especially tumor vaccines. 
